Gilder Gagnon Howe & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $150M | Sell |
|
|||||
|
2025
Q2 | $110M | Sell |
|
|||||
|
2025
Q1 | $93.3M | Sell |
|
|||||
|
2024
Q4 | $86M | Sell |
|
|||||
|
2024
Q3 | $106M | Sell |
|
|||||
|
2024
Q2 | $96.9M | Sell |
|
|||||
|
2024
Q1 | $60.6M | Sell |
|
|||||
|
2023
Q4 | $112M | Sell |
|
|||||
|
2023
Q3 | $105M | Sell |
|
|||||
|
2023
Q2 | $114M | Sell |
|
|||||
|
2023
Q1 | $124M | Sell |
|
|||||
|
2022
Q4 | $154M | Sell |
|
|||||
|
2022
Q3 | $133M | Sell |
|
|||||
|
2022
Q2 | $110M | Sell |
|
|||||
|
2022
Q1 | $129M | Sell |
|
|||||
|
2021
Q4 | $142M | Sell |
|
|||||
|
2021
Q3 | $174M | Sell |
|
|||||
|
2021
Q2 | $157M | Sell |
|
|||||
|
2021
Q1 | $131M | Buy |
|
|||||
|
2020
Q4 | $115M | Sell |
|
|||||
|
2020
Q3 | $130M | Buy |
|
|||||
|
2020
Q2 | $131M | Sell |
|
|||||
|
2020
Q1 | $100M | Sell |
|
|||||
|
2019
Q4 | $108M | Sell |
|
|||||
|
2019
Q3 | $76.7M | Sell |
|
|||||
|
2019
Q2 | $71M | Sell |
|
|||||
|
2019
Q1 | $92.3M | Buy |
|
|||||
|
2018
Q4 | $69.6M | Sell |
|
|||||
|
2018
Q3 | $95.3M | Sell |
|
|||||
|
2018
Q2 | $108M | Sell |
|
|||||
|
2018
Q1 | $144M | Sell |
|
|||||
|
2017
Q4 | $155M | Buy |
|
|||||
|
2017
Q3 | $132M | Sell |
|
|||||
|
2017
Q2 | $94.5M | Sell |
|
|||||
|
2017
Q1 | $61.8M | Sell |
|
|||||
|
2016
Q4 | $46.1M | Sell |
|
|||||
|
2016
Q3 | $92.3M | Sell |
|
|||||
|
2016
Q2 | $77.3M | Sell |
|
|||||
|
2016
Q1 | $88.8M | Sell |
|
|||||
|
2015
Q4 | $139M | Sell |
|
|||||
|
2015
Q3 | $120M | Sell |
|
|||||
|
2015
Q2 | $181M | Sell |
|
|||||
|
2015
Q1 | $183M | Sell |
|
|||||
|
2014
Q4 | $189M | Sell |
|
|||||
|
2014
Q3 | $155M | Sell |
|
|||||
|
2014
Q2 | $126M | Buy |
|
|||||
|
2014
Q1 | $129M | Buy |
|
|||||
|
2013
Q4 | $122M | Sell |
|
|||||
|
2013
Q3 | $123M | Buy |
|
|||||
|
2013
Q2 | $52M | Buy |
|